Research programme: HPK1 knock-out CAR T-cell therapies - Abound Bio/Xi'An Yufan Biotechnology
Alternative Names: HPK1 knock-out CAR T-cell therapies- Abound Bio/Xi'An Yufan BiotechnologyLatest Information Update: 23 Jun 2022
At a glance
- Originator Abound Bio; Xi'An Yufan Biotechnology
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Cancer